Document Detail

Fingolimod treatment in multiple sclerosis leads to increased macular volume.
MedLine Citation:
PMID:  23223539     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: To determine whether fingolimod, an oral sphingosine-1-phosphate receptor modulator approved for treatment of multiple sclerosis (MS), generally leads to increased retinal tissue volume.
METHODS: In this longitudinal observational study, we compared changes in macular volume on spectral-domain optical coherence tomography (OCT) between consecutive patients with MS who initiated fingolimod and a matched reference cohort of patients with MS never exposed to the drug. The primary reference cohort was matched based on time interval between OCT examinations. A secondary reference cohort was matched based on age and disease duration. Change in macular volume within each group was analyzed using the paired t test. Change in macular volume between groups was examined using multiple linear regression.
RESULTS: Macular volume increased by a mean of 0.025 mm3 (95% confidence interval [CI] +0.017 to +0.033, p < 0.001) in the 30 patients with MS who initiated fingolimod over a mean follow-up time of 5 months (SD 3). Macular volume did not significantly change over a mean follow-up time of 6 months (SD 4) in a comparison group of 30 patients with MS never treated with fingolimod (mean change of -0.003 mm3, 95% CI -0.009 to +0.004, p = 0.47). Overall, 74% of eyes in the fingolimod-treated group exhibited an increase in macular volume vs. 37% of eyes in the comparison group.
CONCLUSION: Initiation of fingolimod in MS is associated with a modest, relatively rapid increase in macular volume.
Rachel Nolan; Jeffrey M Gelfand; Ari J Green
Related Documents :
2923849 - A cephalometric investigation of overjet changes in fifty severe class ii division i ma...
2301299 - A comparison of apical root resorption during orthodontic treatment in endodontically t...
15915099 - Le fort iii advancement osteotomy in the growing child affected by crouzon's and apert'...
24612029 - Abstracts.
18405819 - Long-term effectiveness of the continuous and the sectional archwire techniques in leve...
8130239 - Development of overjet and dentoskeletal relations in unilateral cleft lip and palate b...
20708229 - Fertility of swamp buffalo following the synchronization of ovulation by the sequential...
20488319 - A comparative analysis of the outcomes of aortic cuffs and converters for endovascular ...
2597479 - Improvement of peripheral circulation by low density lipoprotein adsorption.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2012-12-05
Journal Detail:
Title:  Neurology     Volume:  80     ISSN:  1526-632X     ISO Abbreviation:  Neurology     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-01-08     Completed Date:  2013-03-01     Revised Date:  2013-07-11    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  139-44     Citation Subset:  AIM; IM    
Multiple Sclerosis Center, UCSF Department of Neurology, San Francisco, CA, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Immunosuppressive Agents / therapeutic use*
Linear Models
Longitudinal Studies
Macula Lutea / pathology*
Multiple Sclerosis / drug therapy*,  pathology
Propylene Glycols / therapeutic use*
Receptors, Lysosphingolipid / antagonists & inhibitors
Retinal Neurons / pathology
Sphingosine / analogs & derivatives*,  therapeutic use
Tomography, Optical Coherence
Grant Support
Reg. No./Substance:
0/Immunosuppressive Agents; 0/Propylene Glycols; 0/Receptors, Lysosphingolipid; 123-78-4/Sphingosine; 3QN8BYN5QF/fingolimod
Comment In:
Neurology. 2013 Jan 8;80(2):128-9   [PMID:  23223537 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Have CT--will travel: To boldly go where no scan has gone before.
Next Document:  Warfarin treatment and thrombolysis: How to persuade procrastinators?